Motivations and hesitations for cervical cancer screening: considerations for scale-up of human papilloma virus (HPV) testing within HIV care in Zimbabwe Authors: Phibion Manyanga, Anjali Vasavada, Sandra Murwira, Lucia Gondongwe, Ponesai Nyika, Brian K. Moyo, Gloria Gonese, Batsirai Makunike-Chikwinya, Stefan Wiktor, Kerry A. Thomson Published: 2026 ABSTRACT BackgroundConsistent with WHO guidance Zimbabwe is transitioning from annual single visit screen-and-treat using visual inspection with acetic acid and cervicography (VIAC) to HPV testing every three years to screen women living with HIV (WLHIV) for cervical cancer.MethodsWe administered a questionnaire at three public-sector facilities in Zimbabwe to understand reasons why WLHIV accept or decline VIAC and preferences for implementation of HPV testing.ResultsA total of 451 WLHIV completed the questionnaire, of whom 414 (91.8%) accepted VIAC screening and 37 (8.2%) declined screening. Close to 50% of the 37 women who declined screening indicated a preference for HPV testing. The majority of WLHIV (76.3%) had known their HIV positive status for ≥ 5 years and nearly all (99.8%) were on antiretroviral therapy. Among the 414 WLHIV accepting VIAC screening, 323 (78.0%) were re-screening, and 91 (22.2%) were screening for the first time. WLHIV accepting VIAC re-screening were motivated by healthcare workers helping them feel secure about their health (45.8%), compliance with annual screening recommendations (39.6%), and encouragement from a healthcare worker (8.0%). Those accepting VIAC screening for the first time were motivated by encouragement from a healthcare worker (39.6%), compliance with annual screening recommendations (38.5%), and helping them feel secure about their health (17.6%). When asked what screening approach they would prefer in the future, the majority of women accepting re-screening (70.3%) and first-time screeners (89%) indicated a preference for continuing with VIAC screening. The 93 WLHIV with a screening history who indicated a preference for HPV testing were evenly split between preferring provider-collected sampling (13.9%) and self-collected sampling at the health facility (13.6%). Fear of physical discomfort of a pelvic exam (54.1%), worry about the screening result (13.5%), and perceived side effects of VIAC (10.8%) were the most common reasons given by the 37 WLHIV who declined VIAC.ConclusionsFacilities transitioning to HPV testing will need to incorporate client-centered education that acknowledges existing individual commitment to VIAC, explains the benefits of HPV testing, and offers HPV self-sampling for WLHIV who are hesitant to undergo a pelvic exam. Introduction Cervical cancer caused by persistent infection with high-risk human papillomaviruses (HPV) is the fourth most common cancer among women worldwide, and leads to close to 350,00deaths per year [1]. Cervical cancer disproportionately affects women in low- and middle-income countries (LMIC) [2], who account for 85% of cases globally, and these disparities are further exacerbated in settings with high HIV burden. Women living with human immunodeficiency virus (WLHIV) are 6 times more likely to experience persistent infection that progress to high-grade cervical lesions at younger ages than their peers without HIV infection [3–5]. It indicates the number of women at increased risk for developing cervical cancer and highlights the need for screening, monitoring, and early intervention. Many LMIC have established cervical cancer screening programs based on manual visual inspection with acetic acid (VIA) [6]. However, with increased evidence for and availability of molecular-based DNA testing for HPV, many countries are gradually transitioning their approach to cervical cancer screening from VIA to more sensitive HPV testing at a less frequent interval. As part of the 90-70-90 Global Strategy for cervical cancer elimination the World Health Organization (WHO) set a target of 70% of women worldwide to be screened using a high-performance test (such as HPV testing) at least twice in their lifetime [7]. In Zimbabwe, cervical cancer is the most common cancer and the leading cause of female cancer deaths; an estimated 3,000 women are diagnosed and 2,200 die each year of cervical cancer [8, 9]. HIV prevalence among women of reproductive age is 15.3%, and the most recent 2020 Zimbabwe Population-based HIV Impact Assessment estimates that only 45.1% of urban WLHIV and 28.6% of rural WLHIV have ever been screened for cervical cancer [10]. Since 2019, the Zimbabwe technical assistance, training and education center for health (Zim-TTECH) has been supporting the scale-up of cervical cancer screening for WLHIV in Zimbabwe. In 2023 a total of 100,117 WLHIV were screened across 360 public-sector HIV care facilities in five provinces following national guidelines for annual “screen and treat” using visual inspection with acetic acid and cervicography (VIAC). Consistent with the 2021 normative guidance from WHO, Zimbabwe screening guidelines were updated in 2023 specifying HPV testing as the primary screening approach. The national goal is for WLHIV to complete HPV testing every 3 to 5 years followed by VIAC triage to guide treatment eligibility. As of 2024, HPV testing was occurring at a small number of demonstration sites, with future scale-up planned as testing commodities become more readily available. In anticipation of these changes to both the method and frequency of cervical cancer screening we administered a questionnaire to a subset of WLHIV who were offered routine cervical cancer screening at Zim-TTECH supported public sector facilities to assess current acceptability of and motivations for VIAC as well as potential preference for HPV testing when it becomes available. Methods Three Zim-TTECH supported facilities (Glenview Polyclinic, Guruve District Hospital, and Tsholotsho District Hospital) were purposively selected for questionnaire administration to represent varied implementation contexts in terms of facility type, population density, and screening volume. Glenview Polyclinic is an urban outpatient clinic located in the capital city of Harare. Guruve District Hospital and Tsholotsho District Hospital are referral facilities that serve rural communities in Mashonaland Central and Matabeleland North Provinces, respectively. All facilities are operated by the Zimbabwe Ministry of Health and Child Care (MoHCC) with implementation support provided by Zim-TTECH. Cervical cancer screening and treatment through ablative methods or LEEP are provided free of charge in these facilities. The questionnaire was administered to a convenience sample of WLHIV presenting to each facility or affiliated outreach services between February and June 2023. The study focused on WLHIV aged 18–49 years. Although the WHO defines reproductive age as 15–49 years, the lower limit of 18 years was used to align with the age of consent in Zimbabwe, ensuring participants could legally provide informed consent. After each WLHIV ≥ 18 years of age had either accepted or declined routine VIAC screening, a nurse interviewer (different than that who offered and/or conducted VIAC) approached each WLHIV with an invitation to complete a questionnaire. The nurse interviewer obtained and documented verbal informed consent following a standardized script prior to administering a paper-based, 31-item questionnaire, either in Shona or Ndebele depending on the participant’s preferred language. The questionnaire covered self-reported HIV history, cervical cancer screening history, reasons for accepting (or declining) screening, and acceptability of HPV testing as a primary screening method. Prior to asking each participant about preferences for future screening modalities the nurse read a brief script explaining HPV testing and self-sampling to ensure all WLHIV answered these questions with the same knowledge. Paper questionnaires were entered in a CommCare-based system for facility-level data hosted in Zimbabwe and managed by Zim-TTECH. Data were exported from CommCare into Excel and then imported into R Statistical Software (version 2022.07.2) for analysis. Descriptive statistics, including absolute frequencies and percentages for categorical variables and median and interquartile ranges (IQR) for continuous variables were generated using tableone and dplyr packages in R. The evaluation protocol for these questionnaire data was approved by the Medical Research Council of Zimbabwe and reviewed according to the U.S. CDC human research protection procedures. Results A total of 451 WLHIV completed the questionnaire, 414 (91.8%) accepted VIAC screening the same day and 37 (8.2%) declined screening (Table 1). The distribution of participants was relatively balanced across the three participating facilities, with 164 WLHIV from Glenview Clinic (36.4%), 163 WLHIV from Tsholotsho District Hospital (36.1%) and 124 (27.5%) from Guruve District Hospital. The median age of all WLHIV who completed the questionnaire was 40 years (IQR 33–45), 64.1% reported completing secondary school, and 66.3% were currently married. The most commonly reported religious affiliations were Christian (44.3%), Pentecostal (24.4%) or Apostolic (19.7%). The majority of WLHIV (76.3%) had known their HIV positive status for ≥ 5 years and nearly all were on antiretroviral therapy (99.8%). Most WLHIV (74.5%) reported receiving HIV care at the current facility for ≥ 5 years and most (73.4%) reach the facility by walking. Among WLHIV, 69% had been offered VIAC cervical cancer screening more than once in the past, 12.9% had been offered VIAC only once previously, and 16.2% reported it being the first time they were offered screening on the day they completed the questionnaire. Table 1Demographics and HIV care characteristics among Zimbabwean women living with HIV offered VIAC cervical cancer screening N = 451 (%)CharacteristicAccepted Re-Screening Today (N=323, 71.6%)Accepted Screening for the First Time Today (N=91, 20.2%)Declined Screening Today (N=37, 8.2%)Total (N=451, 100%) Health Facility 1 Glenview Poly Clinic138 (42.7)17 (18.7)9 (24.3)164 (36.4) Guruve District Hospital103 (31.9)7 (7.7)14 (37.8)124 (27.5) Tsholotsho District Hospital86 (25.3)67 (73.6)14 (37.8)163 (36.1)Median age, years (IQR)40 (33-45)35 (30-44)41 (33-46)40 (33-45) Age Category 18-2001 (1.1)2 (5.4)3 (0.7) 21-3045 (13.9)25 (27.5)7 (18.9)77 (17.1) 31-40124 (38.4)31 (34.1)9 (24.3)164 (36.4) 41-49138 (42.7)34 (37.4)19 (51.4)207 (45.9) Reported Parity 07 (2.2)5 (5.5)7 (18.9)16 (3.5) 146 (14.2)21 (23.1)2 (5.4)75 (16.6) 2-3161 (49.8)40 (44.0)16 (48.4)214 (47.5) ≥4109 (33.7)25 (27.5)12 (32.4)146 (32.4) Highest Level of Schooling Completed None10 (3.1)1 (1.1)011 (2.4) Primary96 (29.7)45 (49.5)9 (24.3)150 (33.3) Secondary or higher216 (66.9)45 (49.5)28 (75.7)289 (64.1) Other1 (0.3)001 (0.2) Marital Status Married218 (67.5)61 (67.0)20 (54.1)299 (66.3) Living with partner6 (1.9)006 (1.3) Single20 (6.2)12 (13.2)11 (29.7)43 (9.5) Widowed35 (10.8)10 (11.0)1 (2.7)46 (10.2) Divorced or separated44 (13.6)7 (7.7)5 (13.5)56 (12.4) Refused01 (1.1)01 (0.2) Religion Christian121 (37.5)63 (69.2)16 (43.2)200 (44.3) Pentecost91 (27.9)10 (11.0)10 (27.0)111 (24.4) Apostolic72 (22.3)98 (21.6)89 (19.7) None11 (3.4)4 (4.4)1 (2.7)16 (3.5) Muslim8 (2.5)008 (1.8) Protestant16 (5.0)5 (5.4)021 (0.9) Other24 (1.2)02 (5.4)6 (2.7) Usual modality of travel to facility Walk248 (76.8)65 (71.4)18 (48.6)331 (73.4) Bus or shared transport65 (20.1)15 (16.5)18 (48.6)98 (21.7) Bicycle/Drive/Other10 (3.1)11 (12.1)1 (2.7)22 (4.9) Time to travel to facility Less than 30 min157 (48.6)29 (31.9)13 (35.1)199 (44.1) 30–60 min103 (31.9)43 (47.3)13 (35.1)159 (35.3) 61–90 min28 (8.7)14 (15.4)7 (18.9)49 (10.9) Time since HIV Diagnosis 24 (5.3) Less than 6 months3 (0.9)19 (20.9)2 (5.4)7 (1.6) 6-11 months6 (1.9)01 (2.7)30 (6.7) 1-2 years21 (6.5)6 (6.6)3 (8.1)44 (10.0) 3-4 years34 (10.5)9 (9.9)2 (5.4)344 (76.3) ≥5 years258 (79.9)57 (62.6)29 (78.4)1 (0.2) Refused to answer1 (0.3)001 (0.2) Years coming to facility for HIV care 26 (5.8) Less than 6 months7 (2.2)17 (18.7)2 (5.4)9 (2.0) 6-11 months6 (1.9)1 (1.1)2 (5.4)32 (7.1) 1-2 years24 (7.4)5 (5.5)3 (8.1)45 (10.2) 3-4 years35 (10.8)8 (8.8)3 (8.1)335 (74.5) ≥5 years250 (77.4)59 (64.8)27 (73.0)2 (0.4) Refused to answer1 (0.3)1 (1.1)02 (0.4)Partner Knowledge of HIV Status (among WLHIV who are partnered, N=305)300 (98.4) Yes222 (99.1)58 (95.1)20 (100.0)5 (1.6) No2 (0.9)3 (4.9)0 Table 1Demographics and HIV care characteristics among Zimbabwean women living with HIV offered VIAC cervical cancer screening N = 451 (%)CharacteristicAccepted Re-Screening Today (N=323, 71.6%)Accepted Screening for the First Time Today (N=91, 20.2%)Declined Screening Today (N=37, 8.2%)Total (N=451, 100%) Health Facility 1 Glenview Poly Clinic138 (42.7)17 (18.7)9 (24.3)164 (36.4) Guruve District Hospital103 (31.9)7 (7.7)14 (37.8)124 (27.5) Tsholotsho District Hospital86 (25.3)67 (73.6)14 (37.8)163 (36.1)Median age, years (IQR)40 (33-45)35 (30-44)41 (33-46)40 (33-45) Age Category 18-2001 (1.1)2 (5.4)3 (0.7) 21-3045 (13.9)25 (27.5)7 (18.9)77 (17.1) 31-40124 (38.4)31 (34.1)9 (24.3)164 (36.4) 41-49138 (42.7)34 (37.4)19 (51.4)207 (45.9) Reported Parity 07 (2.2)5 (5.5)7 (18.9)16 (3.5) 146 (14.2)21 (23.1)2 (5.4)75 (16.6) 2-3161 (49.8)40 (44.0)16 (48.4)214 (47.5) ≥4109 (33.7)25 (27.5)12 (32.4)146 (32.4) Highest Level of Schooling Completed None10 (3.1)1 (1.1)011 (2.4) Primary96 (29.7)45 (49.5)9 (24.3)150 (33.3) Secondary or higher216 (66.9)45 (49.5)28 (75.7)289 (64.1) Other1 (0.3)001 (0.2) Marital Status Married218 (67.5)61 (67.0)20 (54.1)299 (66.3) Living with partner6 (1.9)006 (1.3) Single20 (6.2)12 (13.2)11 (29.7)43 (9.5) Widowed35 (10.8)10 (11.0)1 (2.7)46 (10.2) Divorced or separated44 (13.6)7 (7.7)5 (13.5)56 (12.4) Refused01 (1.1)01 (0.2) Religion Christian121 (37.5)63 (69.2)16 (43.2)200 (44.3) Pentecost91 (27.9)10 (11.0)10 (27.0)111 (24.4) Apostolic72 (22.3)98 (21.6)89 (19.7) None11 (3.4)4 (4.4)1 (2.7)16 (3.5) Muslim8 (2.5)008 (1.8) Protestant16 (5.0)5 (5.4)021 (0.9) Other24 (1.2)02 (5.4)6 (2.7) Usual modality of travel to facility Walk248 (76.8)65 (71.4)18 (48.6)331 (73.4) Bus or shared transport65 (20.1)15 (16.5)18 (48.6)98 (21.7) Bicycle/Drive/Other10 (3.1)11 (12.1)1 (2.7)22 (4.9) Time to travel to facility Less than 30 min157 (48.6)29 (31.9)13 (35.1)199 (44.1) 30–60 min103 (31.9)43 (47.3)13 (35.1)159 (35.3) 61–90 min28 (8.7)14 (15.4)7 (18.9)49 (10.9) Time since HIV Diagnosis 24 (5.3) Less than 6 months3 (0.9)19 (20.9)2 (5.4)7 (1.6) 6-11 months6 (1.9)01 (2.7)30 (6.7) 1-2 years21 (6.5)6 (6.6)3 (8.1)44 (10.0) 3-4 years34 (10.5)9 (9.9)2 (5.4)344 (76.3) ≥5 years258 (79.9)57 (62.6)29 (78.4)1 (0.2) Refused to answer1 (0.3)001 (0.2) Years coming to facility for HIV care 26 (5.8) Less than 6 months7 (2.2)17 (18.7)2 (5.4)9 (2.0) 6-11 months6 (1.9)1 (1.1)2 (5.4)32 (7.1) 1-2 years24 (7.4)5 (5.5)3 (8.1)45 (10.2) 3-4 years35 (10.8)8 (8.8)3 (8.1)335 (74.5) ≥5 years250 (77.4)59 (64.8)27 (73.0)2 (0.4) Refused to answer1 (0.3)1 (1.1)02 (0.4)Partner Knowledge of HIV Status (among WLHIV who are partnered, N=305)300 (98.4) Yes222 (99.1)58 (95.1)20 (100.0)5 (1.6) No2 (0.9)3 (4.9)0 Demographics and HIV care characteristics among Zimbabwean women living with HIV offered VIAC cervical cancer screening N = 451 (%) Among the 414 WLHIV accepting VIAC screening, 323 (78.0%) were re-screening, and 91 (22.2%) were screening for the first time. WLHIV who had previously been screened reported screening within the past 12 months (25.7%), 1–2 years ago (68.7%), or more than 2 years ago (5.6%) (Table 2). When WLHIV accepting VIAC re-screening were asked what motivated them to complete cervical cancer screening, the top three responses were: helping them feel secure about their health (45.8%), following recommended guidelines that WLHIV should receive annual screening (39.6%), and encouragement from a healthcare worker (8.0%). WLHIV accepting VIAC screening for the first time were mostly motivated by encouragement from a healthcare worker (39.6%), followed by recommended guidelines that WLHIV receive annual screening (38.5%), and reassurance about their health (17.6%). When asked what screening approach they would prefer in the future, most women accepting re-screening (70.3%) and most first-time screeners (89%) indicated a preference for continuing with VIAC screening. Table 2Cervical cancer screening history and preferences among Zimbabwean women living with HIV offered VIAC cervical cancer screening N=451 (%)Accepted Re-Screening Today (N=323, 71.6%)Accepted Screening for the First Time Today (N=91, 20.2%)Declined Screening Today (N=37, 8.2%)Total (N=451, 100%) Number of Times offered cervical cancer screening at current facility First time today2 (0.6)66 (72.5)5 (13.5)73 (16.2) Once before40 (12.4)10 (11.0)8 (21.6)58 (12.9) More than once before281 (87.0)14 (15.4)16 (43.2)311 (69.0) Refused01 (1.1)8 (21.6)9 (2.0) Time since last cervical cancer screening Never Screened091 (100.0)19 (51.3)110 (24.4) Within last 12 Months83 (25.7)06 (16.2)89 (19.7) 1-2 years ago222 (68.7)07 (18.9)229 (50.8) More than 2 years ago18 (5.6)04 (10.8)22 (4.9) Refused001 (2.7)1 (0.22) Previous positive screen and/or treatment for cervical lesions Yes49 (15.2)2 (2.2)3 (8.1)54 (12.0) No272 (84.2)80 (87.9)28 (75.7)380 (84.3) Unsure2 (0.6)2 (2.2)04 (0.9) Refused to answer07 (7.7)6 (16.2)13 (2.9) Primary reason to accept cervical cancer screening Yearly screening recommended for WLHIV128 (39.6)35 (38.5)N/A163 (39.4) Experiencing concerning symptoms10 (3.1)2 (2.2)N/A12 (2.9) Reassurance about health148 (45.8)16 (17.6)N/A164 (39.4) Encouragement by friend or family member8 (2.5)1 (1.1)N/A9 (2.2) Encouragement by health care worker26 (8.0)36 (39.6)N/A62 (15.0) Previous positive result2 (0.6)0N/A2 (0.5) Other31 (2.5)1 (1.1)N/A2 (0.5) Primary reason to decline cervical cancer screening Physical discomfort of pelvic examN/AN/A20 (54.1)20 (54.1) Worried about resultsN/AN/A5 (13.5)5 (13.5) Side effects of VIACN/AN/A4 (10.8)4 (10.8) Traditions/personal beliefsN/AN/A2 (5.4)2 (5.4) Require partner approvalN/AN/A1 (2.7)1 (2.7) Extra time needed for VIACN/AN/A1 (2.7)1 (2.7) Not concerned about cervical lesionsN/AN/A2 (5.4)2 (5.4) RefusedN/AN/A2 (5.4)2 (5.4) Preferred type of future cervical cancer screening VIAC screening227 (70.3)81 (89.0)5 (13.5)313 (69.4) HPV testing93 (28.7)9 (9.9)18 (48.6)120 (26.6) HPV testing (provider collected)45 (13.9)7 (7.7)8 (21.6)60 (13.3) HPV testing (self-collected, facility)44 (13.6)2 (2.2)4 (10.8)50 (11.1) HPV testing (self-collected, home)4 (1.2)06 (16.2)10 (2.2) None of the above3 (0.9)01 (2.7)4 (0.9) Refused to answer01 (1.1)13 (35.1)14 (3.1)1Combined outreach and static facilities2Other religions include: Traditional Ndebele, Traditional Healer3Other reasons include: WLHIV’s status as a health care worker, and choosing to screen because it is a free service Table 2Cervical cancer screening history and preferences among Zimbabwean women living with HIV offered VIAC cervical cancer screening N=451 (%)Accepted Re-Screening Today (N=323, 71.6%)Accepted Screening for the First Time Today (N=91, 20.2%)Declined Screening Today (N=37, 8.2%)Total (N=451, 100%) Number of Times offered cervical cancer screening at current facility First time today2 (0.6)66 (72.5)5 (13.5)73 (16.2) Once before40 (12.4)10 (11.0)8 (21.6)58 (12.9) More than once before281 (87.0)14 (15.4)16 (43.2)311 (69.0) Refused01 (1.1)8 (21.6)9 (2.0) Time since last cervical cancer screening Never Screened091 (100.0)19 (51.3)110 (24.4) Within last 12 Months83 (25.7)06 (16.2)89 (19.7) 1-2 years ago222 (68.7)07 (18.9)229 (50.8) More than 2 years ago18 (5.6)04 (10.8)22 (4.9) Refused001 (2.7)1 (0.22) Previous positive screen and/or treatment for cervical lesions Yes49 (15.2)2 (2.2)3 (8.1)54 (12.0) No272 (84.2)80 (87.9)28 (75.7)380 (84.3) Unsure2 (0.6)2 (2.2)04 (0.9) Refused to answer07 (7.7)6 (16.2)13 (2.9) Primary reason to accept cervical cancer screening Yearly screening recommended for WLHIV128 (39.6)35 (38.5)N/A163 (39.4) Experiencing concerning symptoms10 (3.1)2 (2.2)N/A12 (2.9) Reassurance about health148 (45.8)16 (17.6)N/A164 (39.4) Encouragement by friend or family member8 (2.5)1 (1.1)N/A9 (2.2) Encouragement by health care worker26 (8.0)36 (39.6)N/A62 (15.0) Previous positive result2 (0.6)0N/A2 (0.5) Other31 (2.5)1 (1.1)N/A2 (0.5) Primary reason to decline cervical cancer screening Physical discomfort of pelvic examN/AN/A20 (54.1)20 (54.1) Worried about resultsN/AN/A5 (13.5)5 (13.5) Side effects of VIACN/AN/A4 (10.8)4 (10.8) Traditions/personal beliefsN/AN/A2 (5.4)2 (5.4) Require partner approvalN/AN/A1 (2.7)1 (2.7) Extra time needed for VIACN/AN/A1 (2.7)1 (2.7) Not concerned about cervical lesionsN/AN/A2 (5.4)2 (5.4) RefusedN/AN/A2 (5.4)2 (5.4) Preferred type of future cervical cancer screening VIAC screening227 (70.3)81 (89.0)5 (13.5)313 (69.4) HPV testing93 (28.7)9 (9.9)18 (48.6)120 (26.6) HPV testing (provider collected)45 (13.9)7 (7.7)8 (21.6)60 (13.3) HPV testing (self-collected, facility)44 (13.6)2 (2.2)4 (10.8)50 (11.1) HPV testing (self-collected, home)4 (1.2)06 (16.2)10 (2.2) None of the above3 (0.9)01 (2.7)4 (0.9) Refused to answer01 (1.1)13 (35.1)14 (3.1)1Combined outreach and static facilities2Other religions include: Traditional Ndebele, Traditional Healer3Other reasons include: WLHIV’s status as a health care worker, and choosing to screen because it is a free service Cervical cancer screening history and preferences among Zimbabwean women living with HIV offered VIAC cervical cancer screening N=451 (%) 1Combined outreach and static facilities 2Other religions include: Traditional Ndebele, Traditional Healer 3Other reasons include: WLHIV’s status as a health care worker, and choosing to screen because it is a free service A total of thirty-seven WLHIV (8.2%) declined cervical cancer screening. Of these, 78.4% had known their HIV status for ≥ 5 years, and 73.0% had been attending the same facility for ≥ 5 years. Despite this long-term engagement in care, 75.7% had never been screened, even though many had previously been offered screening more than once (43.2%) or once (21.6%). This indicates that repeated offering alone is not sufficient to ensure uptake. The main reasons for screening refusal were fear of physical discomfort during the pelvic exam (54.1%), worry about the screening result (13.5%), and perceived side effects of VIAC (10.8%). When asked about preferred approaches in the future, 48.6% reported a preference for HPV testing, 13.5% for VIAC, and 35.1% declined to answer. Among the 18 women favoring HPV testing, preferences included provider-collected sampling (21.6%), self-collection at home (16.2%), and self-collection at the health facility (13.6%). These findings suggest that refusals are shaped more by personal concerns than by access or opportunity, and that offering HPV-based screening options, including self-sampling, may help to address some of this gap. Discussion HPV testing holds great promise to improve the effectiveness of secondary prevention of cervical cancer in countries with a high dual burden of HIV and cervical cancer. In these settings, it is critical to understand client motivations and preferences in the current context of annual VIAC. Overall, we identified a high acceptance of screening and commitment to VIAC among WLHIV receiving routine HIV care at public-sector facilities in Zimbabwe. Our results indicate groups of WLHIV for whom current screening efforts have been successful, as well as identify areas where education and service delivery can be strengthened in advance of or concurrent to the transition from VIAC to HPV testing for primary screening. Most of the respondents knew their HIV status and were receiving antiretroviral therapy (ART) and had been receiving care at the same health facility for ≥ 5 years. However, the majority of WLHIV accepting screening for the first time reported that it was the first time they were offered screening and the majority of WLHIV declining screening reported they had been offered screening before, highlighting a need for continued demand creation and counselling on the importance of screening as well as repeated invitations and reminders for screening integrated into routine HIV care. Integration of cervical cancer screening into primary care, including integration into routine HIV care for WLHIV, was found to result in higher acceptance of cervical cancer screening in both Kenya and Uganda [11]. In Malawi, the country with the highest cervical cancer mortality in the world, integration of cervical cancer screening into routine HIV care services resulted in a 10-fold increase in uptake of cervical cancer screening [12]. The majority of respondents to our questionnaire had job commitments, accessed the facility by walking, and needed ≥ 30 min to reach the facility, underscoring the opportunity costs associated with clinic visits. A systematic review of studies conducted in LMIC showed that access to health facilities was a major factor influencing uptake of cervical cancer screening [13]. Multi-month dispensing (MMD) of ART and other differentiated care models (DCM) such as community-based ART clubs have shown promise at achieving viral suppression while reducing the time burden associated with monthly facility visits for HIV care [14]. While it is critical to offer these client-centered care models to stable WLHIV, there is a tradeoff of reducing the frequency of touch points with healthcare workers for integrated services such as cervical cancer screening. Zim-TTECH uses a manual, color-coded sticker system to identify WLHIV who have never been screened for cervical cancer and those due for rescreening, with dates written to guide healthcare workers. This system is effective for women attending routine visits but has limitations for WLHIV on multi-month dispensing (MMD) who do not visit facilities regularly and may be missed. These could be reached by screening programs leveraging on existing community-based HIV delivery models to maintain contact and provide adherence support. In the context of a longer screening interval coupled with decreased facility visits for WLHIV who are enrolled in MMD or DCM for ART, automated tracking and reminder systems could ensure WLHIV are identified and invited for HPV testing every 3–5 years, as well as document refusals so they can be addressed with tailored counseling on barriers and misperceptions. The median age of WLHIV responding to our questionnaire was 40 years old. It is reassuring that older women are accepting screening given that the risk of cervical lesions increases with age, especially for women who have not participated in prior screening. An Ethiopian study found that women older than 45 years old were eight times more likely to have cervical lesions compared to younger women [15]. However, first-time screening and refusal were observed even in women aged 41–49 years at Zim-TTECH facilities w, despite knowing their HIV status and long term engagement to the same facility, highlighting the critical need for continuous educational messaging that informs and works to shift mindsets, ensuring that WLHIV of all ages within the recommended interval fully appreciate their ongoing risk and the importance of regular screening. As HPV testing is scaled-up as part of Zimbabwe updated screening guidelines, WLHIV will be screened every 3–5 years between the ages of 25 to 49 years. In the effort to screen WLHIV early, but less frequently, older WLHIV who may be at higher risk of undiagnosed advanced HPV disease must not be overlooked. WHO normative guidance further recommends that in settings where specialized tools are not available to fully visualize the cervix of post-menopausal women, those ages 50–65 years who have never been screened, should have at least one HPV test. A systematic review of barriers to WLHIV accepting cervical cancer screening in sub-Saharan Africa identified inadequate knowledge of cervical cancer and screening, low risk perception of the disease, anxiety about screening results and pain, inability to access screening services and the perception of an extra burden following a cervical cancer diagnosis [16], highlighting how complex and muti-faceted this decision making can be. Through our questionnaire, we identified perceived benefits and potential sources of influence on the WLHIV’s decision making about cervical cancer screening that can be capitalized on as facilities continue with VIAC and then modified as public-sector facilities in Zimbabwe transition to HPV testing. WLHIV with a prior history of screening were motivated by the reassurance that VIAC screening provides, as well as by a desire to follow recommendations for yearly screening. WLHIV accepting screening for the first time reported being motivated by encouragement from healthcare workers. The majority in both of these groups preferred to continue with VIAC screening even after the interviewer introduced HPV testing as an alternative option in the future, highlighting that there may be resistance to a new approach for WLHIV who have already adopted routine VIAC. Conversely, the majority of WLHIV declining VIAC screening cited the physical discomfort of a pelvic exam as the main reason for declining screening and about half expressed a preference for HPV testing as a future screening modality. Zimbabwe’s adoption of more sensitive HPV testing for primary cervical cancer screening coupled with a less frequent screening interval of 3–5 years has the advantage of more accurate and earlier detection of HPV disease while reducing annual screening workload and costs on both WLHIV and health systems. Most women demonstrated a preference for VIAC over HPV testing. This preference is likely rooted in limited awareness and knowledge regarding HPV testing, with VIAC being chosen primarily because it was more familiar. Consequently, accompanying the transition to HPV testing with structured community-level demand creation and targeted individual counselling may be beneficial, providing clear explanations of HPV pathogenesis and the rationale for shifting away from annual ‘screen-and-treat’ strategies. Such an approach could enable WLHIV, many of whom have embraced VIAC, to fully understand the clinical benefits of HPV testing and the justification for less frequent screening. Offering self-sampling may increase acceptance of screening among women who have been previously deterred by the speculum guided exam that VIAC requires. In Uganda, the majority of women gave self-sampling high ratings and generally reported less discomfort, humiliation, and ease of screening with self-collected HPV compared to VIA [17]. Healthcare workers can continue to be a source of positive influence and champions for adhering to screening recommendations as shown in our results, however community health workers, family, peers, community opinion leaders, and faith communities should also be considered as additional target groups for community-level sensitization and sources of encouragement for WLHIV to complete screening [18–21]. While our findings did not identify male partners as a primary influence on screening decisions, the high proportion of WLHIV who reported being married and sharing their HIV status with a partner suggest expanding educational messages on the importance to screening to include men. A quarter of the WLHIV who declined screening identified as being part of the Apostolic religion. Although religion was not explored in any depth as part of our current evaluation, a previous qualitative study in rural Manicaland Province found that women who follow the Apostolic faith prioritize prayer and treatment with holy water over clinical healthcare and prevention services, such as cervical cancer screening [22]. Individual healthcare workers could assess the potential influence of religion among WLHIV who decline screening and tailor counselling messages accordingly, while health facility leadership could consider outreach to local religious leaders. Our findings included perspectives from WLHIV who received HIV care at three facilities and may not be generalizable to additional service delivery settings in Zimbabwe or other countries. Responses to interviewer-administered questionnaires are subject to social desirability, however we balanced this by ensuring a different nurse from the one who offered and conducted the VIAC screening administered the questionnaire. Most respondents were learning about HPV testing for the first time while taking the questionnaire and thus their opinions and reported acceptability of HPV testing reported here may be preliminary in response to only the brief information provided as part of the questionnaire script. Our findings here go beyond routinely collected aggregate monitoring data and can guide early implementation of HPV testing in public sector facilities with limited resources. However more in-depth data collection on the acceptability of HPV testing and preferences for sampling modality specific to Zimbabwe may be needed to further guide the national transition to HPV testing for primary screening. We were unable to calculate the median time from ART initiation to first cervical cancer screening, as dates of ART initiation were not collected, and recommend that future evaluations include this measure to better assess timeliness of service delivery. Conclusion WLHIV accepting cervical cancer screening as part of routine HIV care across three public-sector facilities in Zimbabwe were motivated by awareness of annual screening guidelines, encouragement from healthcare workers, and the reassurance of negative results. At the same time, those who declined expressed fears of pelvic exam discomfort, perceived side effects of visual inspection with acetic acid (VIAC), and anxiety about positive outcomes. Among those who declined, there awas an appreciable preference for HPV testing. Efforts to increase coverage of current VIAC programs could be more successful if they are responsive to these motivations and hesitations, as well as adapt as HPV testing is scaled up. Programs could leverage existing motivations by strengthening patient education on the benefits of early detection, embedding provider-initiated counseling that integrates HPV testing as routine HIV care, and reinforcing the peace of mind associated with negative results. At the same time, barriers can be addressed through patient-centered approaches that reduce procedural discomfort, correct misconceptions about side effects, and provide psychosocial support for women who test positive. Leveraging these insights may enhance uptake, ensure sustainability, and strengthen comprehensive HIV care in Zimbabwe at both the community and individual levels. T.